PDS Biotechnology
PDSB
28 hedge funds and large institutions have $1.19M invested in PDS Biotechnology in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
33% more funds holding
Funds holding: 21 → 28 (+7)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.91% more ownership
Funds ownership: 9.36% → 11.27% (+1.9%)
17% less capital invested
Capital invested by funds: $1.43M → $1.19M (-$243K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$665K |
| 2 |
Renaissance Technologies
New York
|
+$328K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$281K |
| 4 |
First Manhattan
New York
|
+$258K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$42K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.64K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.34K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$433 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$1.13K | +653 | New |
|
PDSB Hedge Fund Activity: Q1 2020 in Review
28 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2020, worth a combined $1.19M — down 17% from $1.43M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PDSB positions and 2 closed out — a net gain of 8 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $665K. The largest seller was RegentAtlantic Capital, exiting entirely with an estimated $42K sold.
- 28 institutional investors held PDS Biotechnology (PDSB) as of Q1 2020, up from 21 in Q4 2019.
- Funds reported $1.19M of PDS Biotechnology stock for Q1 2020, down 17% quarter-over-quarter.
- 10 funds opened new PDS Biotechnology positions in Q1 2020 and 2 closed out, a net change of +8 holders.
- The largest PDS Biotechnology buyer in Q1 2020 was Federated Hermes, an estimated $665K added.
- The largest PDS Biotechnology seller in Q1 2020 was RegentAtlantic Capital, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2020.